Karyopharm Therapeutics

358 articles about Karyopharm Therapeutics

• Karyopharm Therapeutics Initiates a Phase 1b Food-Effect Clinical Trial With the Novel Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Sarcomas

  7/31/2013

• Karyopharm Therapeutics Announces Appointment of Paul Brannelly as Senior Vice President of Finance and Administration

  6/13/2013

• Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 American Society of Clinical Oncology Annual Meeting

  6/3/2013

• Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 European Hematology Association Congress

  5/29/2013

• Karyopharm Therapeutics Raises $48.2 Million in Series B Financing

  5/20/2013

• Karyopharm Therapeutics to Present Clinical Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 American Society of Clinical Oncology Annual Meeting

  5/16/2013

• Karyopharm Therapeutics Gets $20.5 Million

  5/14/2013

• Karyopharm Therapeutics Announces 15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association for Cancer Research (AACR) Meeting

  3/26/2013

• Karyopharm Therapeutics Initiates Treatment of Patients With Acute Myeloid Leukemia (AML) in Phase 1 Trial With Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE)

  1/17/2013

• Karyopharm Therapeutics Recognizes the Contributions of Co-Founder Ronald DePinho, MD

  11/1/2012

• Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in Cancer

  10/31/2012

• Karyopharm Therapeutics Announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)

  8/2/2012

• Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers

  7/25/2012

• Karyopharm Therapeutics Announces Appointment of Co-founder Dr. Ronald DePinho to the National Academy of Sciences

  5/8/2012

• Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association for Cancer Research (AACR) Meeting

  3/7/2012

• Karyopharm Therapeutics Announces Presentations by Seven Collaborators Showing Major Progress in Advancing Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at American Society of Hematology (ASH) Meeting

  11/8/2011

• Karyopharm Therapeutics Raises $10 Million More in Series A Round

  11/2/2011

• Karyopharm Therapeutics and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors

  10/11/2011